The Data Quality Illusion: Why Aggregated EHR Feeds Often Fails
In the life sciences industry, "lab data" is often treated as a commodity. The assumption is that a...
Tracking the Shift: Real-World Adoption of Emerging IHC Markers in Early 2026
Moving beyond the "hype" to seeing actual testing adoption on the ground.
The New Precision Oncology Battleground: Tracking FOLR1, CLDN18.2, and cMET
As Antibody-Drug Conjugates (ADCs) reshape the therapeutic landscape, commercial success depends on...
Shining a Light on Colorectal Cancer Awareness Month
Shining a Light on Colorectal Cancer Awareness Month March is Colorectal Cancer Awareness Month, a...
Keeping the Focus on Kidney Health: Beyond World Kidney Day and the Nuances of CKD
World Kidney Day, observed yesterday on March 13, served as a powerful reminder of the critical...
Beyond Claims: The True Value of Lab Data in Prostate Cancer Therapy Commercialization
Prostate cancer (PC) remains a significant men's health concern, demanding innovative treatment...
Optimizing CLL Commercial Strategies with Lab Insights
Chronic Lymphocytic Leukemia (CLL) presents a complex treatment landscape. While advancements have...
Supporting HAE Commercial Teams with Prognos Health Lab Data
Hereditary angioedema (HAE) is a rare and debilitating condition affecting an estimated 1 in 50,000...
Illuminating Acromegaly: Lab Data Can Change HCP Engagement
Acromegaly, a rare hormonal disorder caused by excess growth hormone (GH) production, often goes...
Rapidly Identifying HCPs Treating AML: The Lab Data Advantage
Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow,...